Discontinued — last reported Q4 '25
ResMed Share Buybacks decreased by 0.0% to $175.01M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 133.3%, from $75.03M to $175.01M.
High repurchases often signal management's confidence in the company's valuation or a strategy to improve earnings per share.
The cash outflow associated with the company buying back its own shares from the open market. This is a primary method f...
Common among mature, cash-generative companies; peers in the healthcare sector often balance this with R&D investment.
share_repurchases| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $50.01M | $50.00M | $50.00M | $50.01M | $74.99M | $75.03M | $100.01M | $150.01M | $175.01M | $175.01M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | -0.0% | +0.0% | +0.0% | +50.0% | +0.1% | +33.3% | +50.0% | +16.7% | -0.0% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | +50.0% | +50.1% | +100.0% | +200.0% | +133.4% | +133.3% |